Scientific Sessions


On This Page:

To search a full listing of sessions available at this year’s conference, use the AAIC Interactive Program Guide.


Plenary Sessions

10:30 - 11:15 a.m.

Association Welcome

Session: PL-01-01

11:15 - 11:45 a.m.

Understanding the Earliest Phases of Alzheimer’s Disease

Marilyn Albert
Johns Hopkins University School of Medicine, USA
Theme: Therapeutics
Session: PL-01-02

10:30 - 11 a.m.

Sleep, Brain and Cognition

Ruth M. Benca
University of California, Irvine, USA
Theme: Therapeutics
Session: PL-02-01

11 - 11:30 a.m.

Alzheimer’s Disease Blood-Based Biomarkers and AD Control

SangYun Kim
Seoul National University, South Korea
Theme: Diagnosis and Prognosis
Session: PL-02-02

10:30 - 11 a.m.

Inge Grundke-Iqbal Award for Alzheimer’s Research: Neurotoxic Reactive Astrocytes Are Induced by Activated Microglia

Shane A. Liddelow, Ph.D.
NYU School of Medicine, USA
Theme: Basic and Translational Science
Session: PL-03-01

11 - 11:30 a.m.

The Epidemiology of Diversity and Dementia

Rachel Whitmer
University of California, Davis, USA
Theme: Public Health and Psychosocial
Session: PL-03-02

10:30 - 11 a.m.

Imaging Neurodegeneration With MRI: What Is New?

David Wolk
University of Pennsylvania Memory Center, USA
Theme: Diagnosis and Prognosis
Session: PL-04-01

11 - 11:30 a.m.

The Cellular Phase of Alzheimer’s Disease

Bart De Strooper
University College London, United Kingdom; University of Leuven, Belgium
Theme: Basic and Translational Science
Session: PL-04-02

10:30 - 11 a.m.

Microglia in Neurodegenerative Conditions

Marco Colonna
Washington University in St. Louis, USA
Theme: Basic and Translational Science
Session: PL-05-01

11 - 11:30 a.m.

Precision Medicine, Population Neuroscience and Comprehensive Care: Partners to Develop and Deliver Effective Prevention and Treatments for Dementia

Sudha Seshadri
The University of Texas Health Science Center at San Antonio, USA
Theme: Public Health & Psychosocial
Session: PL-05-02

Symposium Sessions

Sunday, July 14
  • Disparities in Access to Dementia Care and Prevention [S1-01]
    8 - 9:30 a.m.

    Theme: Public Health and Psychosocial



Dementia Prevention Programs in Urban and Regional Aboriginal Communities in Australia [S1-01-01]

Kylie Radford
University of New South Wales, Australia

Health Literacy and Access to Dementia Care [S1-01-02]

Jennifer Lingler
University of Pittsburgh, USA

Improving the Lives of People with Dementia - The OECD Perspective [S1-01-03]

Elina Suzuki
Organization for Economic Co-operation and Development, France

Dementia As Access Barrier in Palliative Care [S1-01-04]

Jenny T. van der Steen
Leiden University Medical Center, Leiden, Netherlands

Sunday, July 14
  • “Rare Variants” And Their Role In Genetic Etiology And Disease [S1-02]
    8 - 9:30 a.m.

    Theme: Basic and Translational Science



Clustering of Rare Variants in Alzheimer Disease and Related Disorders in the Colombian Population: A Genomic Study [S1-02-01]

Ken Kosik
University of California, USA

The Potential Contribution of Rare Variants to Neurodegenerative Brain Dementia [S1-02-02]

Gary Beecham
The Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami Miller School of Medicine, USA

Whole-Exome Sequencing in 20,197 Persons for Rare Variants in Alzheimer's Disease [S1-02-03]

Richard Mayeux
Columbia University Medical Center, USA

High-Throughput Identification of Noncoding Functional SNPs [S1-02-04]

Gang Li
University of Pittsburgh School of Medicine, USA

Monday, July 15
  • PET and CSF Markers of Neuroinflammation [S2-01]
    8 - 9:30 a.m.

    Theme: Diagnosis and Prognosis



PET Markers of Microglia [S2-01-01]

Robert Innis
National Institute of Mental Health, USA

PET Markers of Astrocytes [S2-01-02]

Elena Rodriguez-Vieitez
Karolinska Institute, Sweden

Neuroinflammation: CSF Perspective [S2-01-03]

Shorena Janelidze
Lund University, Sweden

Fluid Biomarkers of Neuroinflammation [S2-01-04]

Charlotte Teunissen
VU University Medical Center, Netherlands

Monday, July 15
  • Precision Medicine [S2-02]
    8 - 9:30 a.m.

    Theme: Therapeutics



Precision Medicine Model for Targeted NSAID Therapy in AD [S2-02-01]

Sid O'Bryant
University of North Texas Health Science Center, USA

PPAR-Gamma [S2-02-02]

Michael Heneka
German Center for Neurodegenerative Diseases (DZNE), Germany

Insulin-Resistant Sub-Typing [S2-02-03]

Suzanne Craft
Wake Forest School of Medicine, USA

Subtyping of Clinical Subjects through Exosome Analyses [S2-02-04]

Dimitrios Kapogiannis
National Institute on Aging/National Institutes of Health (NIA/NIH), USA

Tuesday, July 16
  • Overlapping AD Pathologies and their Influence on Disease Phenotypes [S3-01]
    8 - 9:30 a.m.

    Theme: Diagnosis and Prognosis



Alzheimer’s and Vascular Disease: A Pathobiological Perspective [S3-01-01]

Costantino Iadecola
Weill Cornell Medicine, USA

Alzheimer’s Disease and Subcortical Vascular Cognitive Impairment (SVCI): Biomarker Perspective [S3-01-02]

Duk Na
Samsung Medical Center; Sungkyunkwan University School of Medicine, Korea, Republic of Korea (South)

Alzheimer’s and Lewy Body Disease: Pathologic Perspective [S3-01-03]

David Irwin
University of Pennsylvania, USA

Alzheimer’s and Lewy Body Disease: Biomarker Perspective [S3-01-04]

Evelien Lemstra
Amsterdam University Medical Centers, Netherlands

Tuesday, July 16
  • Responder Analyses Leading to Hypothesis Generation for Prospective Study Designs [S3-02]
    8 - 9:30 a.m.

    Theme: Therapeutics



Statistical Challenges With Responder Analysis in Exploratory Settings [S3-02-01]

Suzanne Hendrix
Pentara Corporation, USA

Multi-Crossover Randomized Control Design Approaches Based on Analyses of Responder/Non-Responder Outcomes [S3-02-02]

Steven Arnold Massachusetts General Hospital, USA; Harvard Medical School, USA
To be announced.

Statistical Considerations for Efficient Designs within a Platform Trial Approach [S3-02-03]

Karen Messer
University of California San Diego, USA

Determining Whether Identification of a Responder Sub-Group Is Truly Hypothesis Generating [S3-02-04]

Eric Siemers
Siemers Integration LLC, USA

Wednesday, July 17
  • National Dementia Registries: Quality Control and Recruitment of Research Participants [S4-01]
    8 - 9:30 a.m.

    Theme: Public Health and Psychosocial



Identifying Elders at Risk for Cognitive Decline Using the Brain Health Registry (BHR) [S4-01-01]

Michael Weiner
University of California, San Francisco, USA

The Dutch Brain Health Registry for Recruitment of Research Participants [S4-01-02]

Marissa Zwan
VU University Medical Center, Netherlands

Swedish Clinical Quality Registry for Dementia [S4-01-03]

Dorota Religa
Karolinska Institute, Sweden

The Australian Dementia Network (ADNet) Clinical Quality Registry [S4-01-04]

Stephanie Ward
Monash University, Australia

Thursday, July 18
  • Delirium in Dementia: A Translational Aspect [S5-01]
    8:30 - 10 a.m.

    Theme: Basic and Translational Science



Description and Impact of Delirium on Dementia [S5-01-01]

Daniel Davis
University College London, United Kingdom

Biomarkers in Delirium [S5-01-02]

Gideon Caplan
University of New South Wales, Australia

Neurobiology of Delirium and Its Intersection with Dementia: Insights from Animal Models [S5-01-03]

Colm Cunningham
Trinity College Dublin, Ireland

Systemic Inflammation Signaling to the Brain [S5-01-04]

Roosmarijn Vandenbroucke
Ghent University, Belgium

Thursday, July 18
  • Focused Topic Session: Review of Developments in Disease Modifying Strategies for Alzheimer’s Disease: A Focus on Anti-Amyloid Strategies [FTS5-01]
    8:30 - 10 a.m.



Immunotherapy in Alzheimer Disease: Mechanisms of Monoclonal Antibodies in Development [FTS5-01-01]

Christopher van Dyck
Yale School of Medicine, USA

Correlating Cognitive Outcomes with Patient Specific Biomarkers in Alzheimer’s Disease [FTS5-01-02]

Jose Luis Molinuevo
ICN Hospital Clinic i Universitari, Spain

A Pharmacokinetic / Pharmacodynamic Evaluation of Imaging Biomarkers of Alzheimer's Disease [FTS5-01-03]

Tammie Benzinger
Knight Alzheimer's Disease Research Center, USA

The Amyloid Hypothesis: Latest Update in the Context of Recent Trial Evidence [FTS5-01-04]

Reisa Sperling
Brigham and Women's Hospital, USA

Panel Discussion [FTS5-01-05]

Presentation Speakers

Become an ISTAART Member

Members of this professional society stay connected to the field through exclusive member benefits and programs. Join for just $30* at the Alzheimer's Association (Booth 500).

*Offer available onsite at AAIC (through 7/18/19). Applies only to registrants who paid the non-member fee.

join today

Preconferences & Educational Workshops

Learn the basics or brush up on your skills by attending an AAIC preconference or educational workshop. These events provide the opportunity to explore the newest findings and practices for the prevention and treatment of Alzheimer's disease and other dementias.

Learn More

Get Our Attendee App

Simplify and enhance your AAIC experience by downloading the ALZ Meetings app, which allows you to build your daily schedules, review abstracts, locate speakers and much more.


Join the Conversation #AAIC19






> 1200px
> 992px
> 768px
< 767px